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PART 1: THE BIRTH OF
NEUROSURGICAL ONCOLOGY
Historical Perspectives and the
Foundational Work That Paved the Way
Neurosurgeons of the late 19th and early 20th
centuries encountered many obstacles. Most
notable among them were an inability to accurately localize the surgical target and inadequate
experience and techniques of working around the
brain. Regarding intrinsic brain tumors, the early
20th century surgeon and neurologist collaborated, based on an early understanding of neurophysiology and neuroanatomy, to localize the
lesion within the skull. Surgeons would often use
large incisions and “brain needles” to help
identify tumors not visible on the brain surface.
With only rudimentary ether–based anesthesia
and little effective hemostasis available, the ﬁrst
brain tumor surgeries were rushed and frequently
fatal endeavors.1 Often, the tumors could not be
found at all.2 The ﬁrst textbook published on
brain surgery was written by neurologist Starr,3
wherein he described 50 brain tumor surgeries
with a 46% recovery rate after successful localization of the tumor. Surgeons were often weary
about delving into the unknowns of the intracranial space solely on the advice of the neurologist. Combining this with an initial surgical
mortality rate greater than 40%, one can see why
brain tumor surgery at the time was not viewed as
an improvement on the natural history of the
disease.
Only in 1905 do we mark the establishment
of neurological surgery as a distinct subspecialty
among surgeons in the United States.4 Advances in operative techniques and improved
understanding of surgery on the nervous system
by Cushing5 and others led to improved patient
outcomes. Perioperative mortality decreased to
10% to 15% over the subsequent 20 years.
However, difﬁculties with tumor visualization
before and during surgery led to partial
ABBREVIATIONS: NCE, noncontrast enhancing; TMZ,
temozolomide.
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resection, subsequent edema, and bleeding,
further increasing surgical risk. To mitigate this
risk, surgeons frequently opted not to replace
the bone ﬂap and in some cases, surgeons advocated for simple removal of the bone ﬂap as
treatment, leading to debate over the role of socalled external decompression in early brain
tumor surgery. Because of an inadequate means
of controlling intracranial pressure, some
postulated whether surgery made tumors grow.
Little was known about the nature of intrinsic
brain tumors. Bailey and Cushing6 published
the ﬁrst histopathological classiﬁcation of intrinsic brain tumors. Around the same time, the
advent of ventriculography and neuroangiography helped lay the foundation for an
era of brain tumor surgery that persisted well
into the second half of the 20th century.7,8
Important developments in anesthesia, the
utilization of antibiotics, and the introduction
of dexamethasone in 1962 to treat cerebral
edema greatly improved the safety of brain
tumor surgery.9 Jelsma and Bucy10 in a landmark publication reported a step-wise decrease
in operative mortality from 48% in 1945 to
1949, to 22% in 1950 to 1961 and down to
2.9% after 1961 with the advent of pre- and
postoperative dexamethasone administration.
Early evidence also supported the intuitive idea
that survival and functional outcomes were
linked to the amount of tumor that could be
removed, and external decompression alone
rarely beneﬁted the patient.10–12
Foster Kennedy humbly summarized the remaining challenges.10
“He who cares for patients suffering from braintumour must bring to his problem much
thought and stout action. There is need also of a
formidable optimism for the dice of the gods are
loaded!”

PART 2: PICTURE CARE IN 1970
To understand how far neurosurgical oncology
has progressed in the past 50 years and chart a
course for the future, ﬁrst picturing neurosurgical
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care in 1970 will be helpful. Surgeons continued to deal with the
problem of localizing the surgical target preoperatively. The ability
to localize the tumor was based on the neurological examination,
and the only images available to suggest the region and extent of a
tumor were the radionuclide brain scan (Figure 1, left) and cerebral
angiograms (Figure 1, right). Angiography would show distortion
of normal neurovascular anatomy by a space-occupying mass, and
in some glioblastomas, abnormal vasculature could be observed in
part of the lesion.
Large craniotomies would be performed over the suspected
region containing the tumor, and a large dural opening was made.
While the brain started to swell, the cortex was incised and an
Elsberg cannula was passed into the brain substance until one
could feel a difference in brain consistency. Once the tumor was
suspected, the lesion would be biopsied using handheld retractors.
If a tumor was conﬁrmed, a rapid removal was attempted while
controlling bleeding with a bipolar forceps and gentle compression. Subtotal resection was common, and patients were often
clinically worse in the immediate postoperative period.
The estimated extent of resection was subjective and generally
based on the surgeon’s observations. Adjuvant therapies were also
limited. Brain swelling was managed with urea or mannitol and
corticosteroids. Although there was some suggestion of effectiveness, the utility of radiation or chemotherapy was yet to be
established or implemented into standard practice.13 The postoperative administration of whole brain radiation therapy was
common a couple of weeks thereafter. To summarize, a patient
diagnosed with a brain tumor in 1970 would be offered surgery
based on only indirect tumor localization, and if they had most of
the tumor resected, they could expect an average survival of 6 to 9
months. Those who aspired to improve the care of patients with
brain tumors were still outpaced by a disease that was yet to come
into full focus.

PART 3: DECADES OF ADVANCEMENT
True advances, especially disruptive innovations, are frequently
met with skepticism. In 1971, Godfrey Hounsﬁeld introduced the
computed tomogram (CT) scan. The neuroradiologist at the
National Neurological Hospital at Queen’s Square in London
“explained to Hounsﬁeld that with pneumoencephalography,
plane tomography, and angiography there was no existing brain
lesion that could not be diagnosed by imaging already. There was
no obvious clinical use for a CT machine as tomograms in general
weren’t really all that useful. He was sent packing.” 14 It was not
until 1973 to 1974 that the EMI CT scanner became readily
available that true advancements in surgery were enabled. This
localization advance also promoted the development of regional
postoperative radiation therapy later in that decade.
In 1971, Paul Lauterbur conceived of nuclear magnetic resonance (NMR) imaging but was met with the same skepticism as
Hounsﬁeld. Lauterbur’s discovery would ultimately lead to the
ﬁrst commercial MRI scanners a decade later. “Lauterbur ﬁled a
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FIGURE 1. Picture care in 1970. Radionucleotide scan in a patient with a
brain tumor (left). Cerebral angiography in a patient with a temporoparietal
glioblastoma (right). Abnormal vasculature is seen in part of a glioblastoma.

preliminary patent disclosure, but he received advice from all sides
that MRI had no imaginable commercial use. He would need to
spend money to ﬁle the actual patent and allowed the 1-year
deadline to pass without ﬁling. He published the method in
Nature after successfully appealing an initial rejection by an editor
who felt this would be of limited specialist interest only.” 14 The
ﬁrst commercial MRI scanner was introduced in 1980. Identiﬁcation of tumors and surgical localization improved remarkably
when MRI technology advanced and was used commonly
in 1984.
However, neurosurgeons began to realize that even the most
effective surgeries would need to be aided by equally effective
postoperative care and adjuvant therapies to improve outcomes for
malignant gliomas. The ﬁrst effective adjuvant therapies were
beginning to take shape, fostered by the foundational work of the
Brain Tumor Cooperative Group in the 1970s led by Walker and
Wilson. Bischloroethyl nitrosourea (BCNU) and radiotherapy in
combination extended the median overall survival from an unacceptable 4.2 to 10 months in their randomized study.15,16
Introduction of adjuvant oncological therapy was a major step
forward and further improved survival for patients with glioblastoma multiforme (GBM). However, further advancements in
subsequent decades proved incremental. Oertel et al17 demonstrated that the overall prognosis of patients with GBM did not
change signiﬁcantly between 1978 and 1995, leading neurosurgeons and oncologists to ask themselves, can we do better? Temozolomide (TMZ), a better tolerated oral alkylating therapy, in
combination with fractionated radiation and further adjuvant
temozolomide, also known as the “Stupp regimen,” has become
the standard of care since 2005 and offered another incremental
increase in survival.18 Further demonstrated survival advantage
has been conferred by the addition of tumor treatment ﬁelds to
the Stupp regimen in select patients.19,20
With growing accessibility of MRI, tumor volumes before and
after surgery could be better studied and mounting evidence for
complete tumor removal further informed neurosurgical decisionmaking. In 2001, Lacroix et al21 identiﬁed that among 416
patients, obtaining a near gross total resection >98% conferred a
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median survival advantage of 4 months (median overall survival
13 months) and any resection >90% conferred some meaningful
survival over those with lesser resections. Sanai et al22 added to our
understanding, ﬁnding that there was a signiﬁcant survival advantage conferred with any extent of resection >78% and the

improvement was incremental, leading to a median survival of
16 months in those who achieved gross total resection. These
results were echoed among other neurosurgical groups, and it
became evident that the postoperative MRI shortly after surgery
was necessary to determine the extent of resection accurately and

FIGURE 2. Left: Diagram of differential density of invading cancer cells surrounding a high-grade primary brain tumor. Invading cells remain after surgery (lower image),
especially within 2 cm of the resection cavity where recurrences most often occur. Right: Pre- and postoperative FLAIR images demonstrate complete resection of the tumor focus
with residual FLAIR hyperintensity surrounding the resection cavity. Reprinted from Smith RR, Holaday HR, and Wilson RG, Transcranial doppler ultrasonography in
neurosurgical practice, Clinical Neurosurgery. 1991; 37:255-274, with permission from the Congress of Neurological Surgeons. FLAIR, ﬂuid-attenuated inversion recovery.
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prognosticate survival.23 In addition, larger glioblastomas at diagnosis did not necessarily portend a worse prognosis than smaller
tumors, and the residual volume after surgery and the extent of
overall resection were found to be independent predictors of
improved overall survival.24,25 As the data advocating for maximal
tumor removal came more sharply into view, data suggesting that
new postoperative deﬁcits led to a signiﬁcant decrease in overall
survival accompanied it.26 Duffau and Mandonnet27 described
the concept of the oncofunctional balance, in which the value of
further resection must be weighed against the potential harm to
the patient, survival beneﬁt, and quality of life. Yong and Lonser28
went on to reﬁne this concept in the context of surgical decisionmaking and the risk of making the patient with a brain tumor
clinically worse. Thus, within the last decade, we have realized that
effective treatment of a patient with brain tumor requires safe,
maximal resection of the contrast-enhancing disease, when possible, but without causing new neurological deﬁcits.26–29
As a means to achieving this result, many tools have been added
to the surgeon’s armamentarium with the goal of safer, more effective surgery. Neuronavigation, ultrasound, and 5-aminolevulinic
acid ﬂuorescence improve on our ability to visualize the tumor
intraoperatively. Diffusion tensor imaging, awake craniotomy, and
neuromonitoring have allowed surgeons to make safer cuts, actively
avoiding the most eloquent cortical areas and subcortical ﬁber
tracts. A meta-analysis of intraoperative neurostimulation for brain
mapping demonstrated improved extent of resection and a signiﬁcant decrease in permanent neurological deﬁcits.30 Greater
insight into neural circuitry and the neurobiology of the mind,
increased computer processing power, and progress in machine
learning allow for optimized preoperative planning and preservation
of critical neuroanatomy.31,32 Intraoperative MRI has been installed in many comprehensive tumor centers, allowing surgeons to
reassess the residual tumor and account for brain shift from the
surgery, signiﬁcantly increasing the likelihood of achieving a
gross total resection.33 Minimally invasive laser ablations can
now offer safe cytoreductive beneﬁt for tumor foci that would
have been unfavorable targets for open surgery.34,35 Similarly,
neuronavigated, minimally invasive brain retractors placed along
critical structures rather than through them allow for microsurgical resection of deeply seated lesions previously believed of
as inoperable.36
Despite complete resection of the observed solid tumor and
adjuvant therapy, high-grade gliomas are characterized by their
relentless progression. The likelihood of recurrence is related to
various aspects of the tumor’s biology and our current treatment
paradigms. There are inﬁltrating tumor cells outside the contrastenhancing portion of lesion, which are difﬁcult to visualize with
current technology and in many cases, more difﬁcult to access
surgically (Figure 2). There is a growing body of evidence focused
on so-called supratotal resection of brain tumors. Li et al37
demonstrated that in a single-center cohort, the median survival could be increased from 14 to 20 months with resection of all
the contrast-enhancing disease and >53% of the noncontrastenhancing (NCE) disease. Molinaro et al38 demonstrated that in
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certain subgroups of patients, the aggressive resection of >90% of
NCE disease conferred signiﬁcant increases in overall survival up
to a median of 36 months. We are beginning to understand that
the beneﬁt of supramarginal resection is also partly affected by the
degree of invasiveness of the tumor. Using mathematical models
of diffusivity, diffuse tumors with a larger portion of ﬂuidattenuated inversion recovery (FLAIR) relative to contrast enhancement were shown to beneﬁt from the most aggressive NCE
resection compared with nodular tumors with relatively smaller
areas of perilesional NCE disease.39 Although the preponderance
of currently available evidence suggests that greater resection of
NCE disease may be beneﬁcial to patients, in a recent systematic
review, the authors suggest that there are insufﬁcient data and
methodology for a broad recommendation in favor of supratotal
resection.40 As we move toward more aggressive resections, a more
nuanced understanding of brain networks and ﬁber tractography combined with effective utilization of superﬁcial and
subcortical stimulation will be essential to prevent new neurological deﬁcits and minimize the morbidity of surgery on our
patients.29–31

PART 4: PRECISION MEDICINE: THE NEXT
DISRUPTIVE INNOVATION
Molecular Biology Advances Lead to
Molecular Therapeutics
Perhaps most disruptive of the recent innovations in neurooncology are the collective biomolecular advances that have
yielded greater understanding of GBM biology. Although median
survivals have increased steadily over the past 20 years, there
remains wide variability when examining the survival of individual
patients. Some patients may respond extraordinarily well to their
adjuvant TMZ, whereas others with a seemingly equivalent tumor
and treatment go on to suffer from aggressive disease and recurrence. The ﬁfth edition of the World Health Organization
classiﬁcation of tumors of the central nervous system published in
2021 well reﬂects the advances in our understanding of disease
biology and illustrates the role that molecular diagnostics have
come to play alongside more traditional immunohistochemistry.41 Identiﬁcation and characterization of speciﬁc GBM molecular features has implications for diagnosis, prognosis, and
prediction of treatment response and increasingly can inform our
surgical objectives as well, ushering us into the molecular era of
neuro-oncology.42–44
Much effort has been invested in identifying and characterizing
speciﬁc mutations that may serve as therapeutic targets in primary
or recurrent glioblastoma including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), the
tyrosine protein kinase mTOR, ﬁbroblast growth factor receptor
(FGFR), the proto-oncogene BRAF, and other genes.45 Although it
is known that tumors with a methylated methylguaninedeoxyribonucleic acid methyltransferase (MGMT) promoter region will have an enhanced response to temozolomide and better
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prognosis, presumably because of downregulation of the MGMT
gene transcription by hypermethylation, this has not translated into
new therapies for patients.19,46 To date, VEGF inhibition with
bevacizumab is the only targeted approach that can improve
progression-free survival in recurrent GBM, but disease recurrence
remains nearly inevitable.47–49 GBM exposed to VEGF inhibition
may respond initially, but the tumor cells that remain can cause
recurrence by upregulating other angiogenic pathways or activating
pathways that enhance invasiveness of the tumor cells without requiring angiogenesis.47 It is likely that by targeting 1 pathway directly,
we may cause a temporary regression, but at the same time, induce an
alteration in the tumor state and microenvironment that enables
recurrence.50 Tumor temporospatial heterogeneity and subclonal
populations thus enable the development of evasive resistance to any
single directed therapy. When considering a potential cure for
glioblastoma, we are not likely to achieve this with a single silver bullet;
rather, the treatment will likely consist of a collection of therapies, all
focused at different areas of the tumor molecular biology.
At present, there remain several biological issues to address
before molecular therapeutics can reach its optimal goal and
potentially become standard of care (Table 1). Research should
focus on the most prevalent and actionable molecular alteration in
a patients’ tumor. The issues of tumor heterogeneity, tumor stem
cells, and the invading tumor cell need to be addressed. In addition, the inevitable resistance development in the tumor cell
population and the common normal tissue toxicity observed in
clinical trials need to be understood and, if possible, avoided.
The question of which genetic or epigenetic alterations are important remains unanswered. Genetic and epigenetic changes that
occur within the tumor microenvironment in response to chemotherapies are also problematic.51 The Glioma Longitudinal Analysis
Consortium is focused on characterizing the molecular alterations
that occur during the course of the disease from diagnosis through
recurrence.52 The group has shown that 70% of tumors had an
increased mutation burden at the time of recurrence.53 They also
demonstrated that treatment with alkylating agents such as temozolomide can induce hypermutation states in glioma and that environmental and treatment-related selective pressures can produce
more aggressive tumor cell subpopulations linked to disease progression and decreased survival.52 Using a pan-European cohort of
176 paired primary and recurrent GBM isocitrate dehydrogenase
gene (IDH) wild-type samples, Draaisma et al54 observed changes in
mutation status for all oncogenes that they examined.

TABLE 1. Remaining Biological Problems for the Development of
Molecular Therapeutics
1. Which molecular abnormalities observed (genomic, epigenomic, or
both) are important?
2. Tumor heterogeneity—in space and time
3. Tumor stem cells—are they the key target?
4. The invading tumor cell—altered sensitivity to treatment?
5. Combating resistance development—it’s inevitable!
6. Normal tissue toxicity—systemic and brain

CLINICAL NEUROSURGERY

TABLE 2. Developing Therapeutics to Speciﬁc Molecular Targets
1. Develop relevant preclinical models
2. Conﬁrm brain delivery in humans
3. Conﬁrm in vivo antitumor activity (identify surgical trial
opportunities)
4. Encourage industry and governmental support for therapeutic
cocktails

Early evidence suggests that recurrent GBM can respond to
personalized treatment based on repeat tissue characterization at
recurrence in selected patients and there are data in support of
histology-agnostic targeted therapy for other malignancies increasingly published over the last several years.55–57 Patients and treatment teams may be missing a valuable opportunity for tissue
characterization at the time of progression or recurrence, particularly
given the favorable safety proﬁle and accuracy of current minimally
invasive biopsy techniques. Recurrent GBM often harbors molecular
features distinct from their primary counterparts.51,58,59 Molecular
evolution of IDH wild-type glioblastomas affects survival and can
inform precision medicine trial design.54 Obtaining multiple tissue
samples from primary and recurrent GBMs, particularly after chemotherapy, will enable further investigation into the alterations to
the tumor microenvironment by treatment and aid in discovery of
molecularly targeted therapies.
To develop precision therapeutics to speciﬁc molecular targets,
several prerequisites are likely to be critical (Table 2). Preclinical
models in the laboratory will be necessary. Conﬁrmation of drug
delivery into the human brain tumor will be important. Conﬁrmation of anticipated in vivo antitumor activity is paramount.
To develop therapeutic cocktails of multiple agents that target
different molecular abnormalities, industry and governmental
support will likely be needed.
As is true in other tumor types, glioblastoma cells undergo
epigenetic changes and develop areas of hypermethylation around
speciﬁc deoxyribonucleic acid (DNA) promoter regions, resulting
in altered gene expression.60,61 Abnormal methylation of conserved
cancer cell DNA regions in promoters known to regulate gene
expression (CpG islands) in cancer cell DNA has been identiﬁed as
a key epigenetic signature that is often unique to different cancer
types.62 Glioblastoma cells shed DNA into the blood stream, and
altered methylation patterns have been studied in plasma cell–free
DNA. CNS tumors including glioblastoma have been accurately
categorized based on DNA methylation proﬁles acquired from
serum samples.63,64 This area of active investigation has potentially
signiﬁcant clinical utility, with the potential for minimally invasive
diagnosis and characterization of a tumor or recurrence through a
simple blood draw, the so-called liquid biopsy.
There is growing recognition of spatial and temporal tumor
heterogeneity, not only in primary brain tumors but also increasingly
in brain metastases.51,58,59,65 These ﬁndings have implications in
clinical trial design because driver mutations present in primary tumors at diagnosis may be absent in the metastatic tumor. Moreover,
clinically actionable driver mutations not found on initial analysis of
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the primary tumor site may be present in up to 50% of metastatic
brain tumors, further underscoring the role for biopsy of recurrent or
metastatic disease sites over time to help guide treatment.55,66,67
The complete realization of precision medicine will likely involve a cocktail of different targeted therapies with the hope of
transforming a patient’s cancer from an aggressive and terminal
illness to a chronic disease, which has been successfully performed
with patients harboring the human immunodeﬁciency virus.68
Patients diagnosed with human immunodeﬁciency virus/acquired
immunodeﬁciency syndrome in the 1980s had an average survival
measured in months, whereas those who receive the diagnosis
today can live a full and healthy life. We can hope that this day will
come for patients suffering from glioblastoma as well. As we guide
patients on increasingly longer journeys living with their disease,
hope itself can be a powerful tool.

PART 5: HOPE SPRINGS ETERNAL
Comprehensive Brain Tumor Centers and the
Patient Experience
Patients routinely describe the moment of a brain tumor diagnosis as one of emotional extremis associated with feeling of
shock, panic, and difﬁculty in processing the information.69–72
Much effort over the past 50 years has been dedicated to providing
these patients with new and advanced ways to study and treat their
cancer. Amid this era of rapid scientiﬁc advancement and progress
in the ﬁeld of glioblastoma management, it is important that we
continue to consider the disease through the eyes of the patient. A
physician’s ability to convey truth while also instilling hope may
be as important to the patient and their family as the medical care
they receive.71,73 Patients need to be supported through the
continuum of their disease process, not just the perioperative
period. To achieve these goals, an emphasis should be placed on
establishing and strengthening collaborative centers for the
management of brain tumors.72
Institutional tumor boards involving neurosurgeons, neurooncologists, and radiation and medical oncologists are essential
for ensuring that patients are receiving the best possible care,
but caring for patients with brain tumors requires much more
than surgery, radiation, and chemotherapy (Figure 3). In his
keynote lecture to the 1988 Congress of Neurological Surgeons,
Rabbi Harold Kushner, the author of When Bad Things Happen
To Good People, noted that “patients with cancer are most afraid
of fear and abandonment.” 71 Although our patients with brain
tumors do not often experience pain, they and their families too
frequently can feel abandoned, especially late in their disease
progression. Comprehensive brain tumor centers are increasing
in number, with the focus of providing patients with a holistic
and supportive network of physicians, nurses, care navigators,
clinical trials teams, psychological support and case management resources, and other dedicated staff to provide support for
patients throughout their continuum of care. Nurse navigators
who are available for questions and communicate between

22 | VOLUME 68 | NUMBER 1 | APRIL 2022

physicians and patients improve the quality of life for the patient
and their family and protect patients from the fear of abandonment.
Support groups help provide a bulwark against the isolation and
stress that often accompanies the role of a caregiver to a patient with
brain cancer. The Hermelin Brain Tumor Center is but one example of such comprehensive brain centers.
Paramount to the patient’s struggle is the ability of the physician to
maintain an atmosphere of hope, even in the face of a grim prognosis.
Our patients have taught us that from their perspective, this is as
important as any surgical treatment that we can offer.71,72,74 Psychosocial support should also be focused on those closest to the
patient, who often bear the burden of care, while their own health
and well-being suffer. Caregivers faced with feelings of helplessness,
isolation, and ﬁnancial difﬁculties should be assisted by providing
frequent and timely communication and support resources. In fact,
increasing caregiver centers are springing up within comprehensive
brain tumor centers around the country.75 Collaborations between
patients, caregivers, and brain tumor center staff such as patient and
family advisory councils can provide an important mechanism for
continuous quality improvement within the comprehensive brain
tumor center. We have found patient and caregiver feedback to be an
invaluable resource to our own comprehensive brain tumor center.

PART 6: LESSONS LEARNED OVER 50 YEARS
Can We Do Better?
The role and impact of a neurosurgical oncologist has evolved
tremendously over the last 50 years, yet we are still faced with the
same question, “Can we do better?”
The way forward should focus on achieving several separate
goals as a consequence of lessons learned over the past 50 years
(Table 3). Surgically, we should strive to develop techniques to
achieve the maximal cytoreductive effect without causing untoward neurological deﬁcits in the patient. We should be most
aggressive with low-grade gliomas because these tumors offer the
highest likelihood of long-term beneﬁt and probably harbor fewer
and less widespread invading tumor cells. After surgery, we
need to focus our efforts on understanding the molecular biology of each tumor. By further developing systems to store and
annotate tumor and serum samples, we can contribute to the
emerging science of molecular diagnostics and precision
therapeutics for brain tumors.76 We should obtain specimens
from multiple tumor regions and, when clinically appropriate,
from invaded brain to enable studies of invading tumor cells.
Because of the cellular complexity of solid tumors, which
contain normal brain elements and inﬁltrating immune cells
along with the tumor cell component, studies of isolated tumor
cells should be encouraged. Perhaps the invading cells have a
novel target to which therapeutics can be directed. When
developing treatments, this research should consider normal
tissue toxicity and tumor cell sensitivity. The development of
targeted, personalized therapies is the next and most promising
frontier in glioblastoma treatment.
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FIGURE 3. A schematic representing a comprehensive multidisciplinary continuum of care model for the patient with a brain tumor.
Reprinted by permission from Copyright Clearance Center: Springer Nature, Journal of Neuro-Oncology, Through the patient’s eyes: the
value of a comprehensive brain tumor center, Robin AM, Walbert T, Mikkelsen, et al, 2014.

Patients with brain tumor, when possible, should be directed
to comprehensive brain tumor centers so that they can have
access to leading-edge therapies and the support services and

CLINICAL NEUROSURGERY

continuum of care that the tumor center provides. Contributing to research endeavors and participating in clinical trials
gives patients and clinicians hope. It is also important to
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TABLE 3. Lessons Learned Over 50 Years in Surgical Neuro-Oncology
Surgical goals
• We cannot remove every last tumor cell, but the fewer cells remaining, the better
• Do not cause deﬁcits
• Use minimally invasive technologies if possible
• Be most aggressive with lower-grade gliomas
Evaluating the tumor molecular proﬁle
• Develop an optimum tumor banking system to collect tissue and serum/blood
• Obtain specimens from multiple tumor regions and invaded brain
• Study isolated tumor cells (eg, single cell RNA sequencing)
• Study invading tumor cells—will we ﬁnd a novel target?
Research efforts
• Supporting research and clinical trials gives the patient and us hope
• Focus on normal tissue toxicity, not just tumor cell sensitivity (as often performed in the past)
• Cancer research is a potent philanthropic stimulus to support all needed efforts
The patient is our most important consideration
• Comprehensive, multidisciplinary tumor boards and programs are optimal
• The care team is as important as us (especially the neuro-oncologist and nurse)
• Communicate throughout with the patient and family—avoid a fear of abandonment
• Improve system processes to lessen anxiety and ensure up-to-date treatment
• Our words mean a lot, our attitude is obvious, give them something to hope for

recognize that cancer research is a potent philanthropic
stimulus that can yield important funds to help support all the
goals mentioned in this article.
Throughout this important work, it is critical to view this
devastating disease through the eyes of the patient. Many
patients remember the precise wording and circumstances
surrounding the moment of their brain tumor diagnosis for the
rest of their lives. That moment is an opportunity for the
neurosurgeon to have a tremendous, positive impact on our
patients and their families. It is the challenging yet rewarding
job of the neurosurgeon to be informative and honest with the
patient, while reassuring them that they will be cared for,
lessening their anxiety and providing realistic hope. When
delivering a new diagnosis, start the conversation by calming the
patient’s and family’s fears, then review the diagnostic ﬁndings,
and discuss the science. Prognoses are based on an average of
survival statistics and mathematical estimations, but every
patient is different. Assure them of up-to-date treatment. Build
the relationship between the care team and the patient family
and focus on their responses and questions. Improvements in
care processes are possible along the care continuum. For

example, when possible, at the follow-up clinic visits during
treatment, the repeat imaging can be performed and the results
can be shared with the patient the same day. This simple process
improvement can signiﬁcantly lessen anxieties for both the
patient and their family. Finally, we need to be aware that the
words we use explaining the situation to the patient mean a lot,
and our attitude is obvious to all. We must provide patients
with the truth, but above all, give them hope.71
For glioblastoma, the role of neurosurgeons from the 1970s to
2020 was based on 3 objectives: obtain a tissue diagnosis, remove
as much tumor as safely possible, and play a role in tumor boards.
However, it is important to realize that with new capabilities, our
role has expanded (Table 4). Neurosurgeons in 2021 and beyond
need to also obtain tissue for molecularly directed precision
therapeutics, consider safely obtaining a tissue biopsy at the time
of recurrence for guiding next-line therapy selection, and play an
active role in the development of comprehensive brain tumor
centers. In summary, neurosurgical oncologists should be innovative and open to change, aggressive (within limits), enablers of
scientiﬁc advances, compassionate and supportive, and leaders in
the multidisciplinary neuro-oncology team. Why are these things

TABLE 4. The Role of a Brain Tumor Surgeon: 1970 to 2020 vs 2021+
Role of a neurosurgeon (1970-2020)
• Obtain a tissue diagnosis
• Remove as much tumor as safely possible
• Play a role in tumor boards
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Role of a neurosurgeon (2021+)
•
•
•
•
•

Obtain a tissue diagnosis
Obtain tissue for molecularly directed precision therapeutics
Remove as much tumor as safely possible
Play an increased role in tumor programs
Consider safely obtaining tissue at recurrence for new therapeutic selection
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important? Because the future of neurosurgical oncology is in our
hands, and the future can be bright.
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